Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
详细信息 查看全文
- 作者：Tereza Lanitis ; Robert Leipold ; Melissa Hamilton…
- 关键词：Venous thromboembolism ; Apixaban ; Vitamin K antagonists ; Cost ; effectiveness
- 刊名：BMC Health Services Research
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：17
- 期：1
- 全文大小：1528KB
- 刊物主题：Public Health; Health Administration; Health Informatics; Nursing Research;
- 出版者：BioMed Central
- ISSN：1472-6963
- 卷排序：17
文摘
BackgroundPrior analyses beyond clinical trials are yet to evaluate the projected lifetime benefit of apixaban treatment compared to low-molecular-weight heparin (LMWH)/vitamin K antagonist (VKA) for treatment of venous thromboembolism (VTE) and prevention of recurrences. The objective of this study is to assess the cost-effectiveness of initial plus extended treatment with apixaban versus LMWH/VKA for either initial treatment only or initial plus extended treatment.